Abstract
Lenvatinib is the first-line therapy for inoperable HCC. However, intrinsic and acquired drug resistance occurs during the treatment period. Autophagy is an adaptive response that favors tumor survival under stress. In the present study, we aim to reveal the unknown autophagic engagement in lenvatinib resistance. Lenvatinib-resistant HCC cell lines and xenograft mouse HCC models were established to identify the key regulator of lenvatinib resistance in HCC. By in vitro functional restoration assays and autophagic flux detection, we demonstrated that the Syntaxin-6 (STX6) -mediated autophagy induced lenvatinib resistance of HCC cells. Mechanistically, Co-immunoprecipitation assay and mass spectrometry indicated that the interactions of STX6 with Beclin1, VTI1A, and VAMP3 facilitated autophagy, leading to the lenvatinib resistance. Additionally, STX6 enhanced the ability of proliferation, migration, and invasion of HCC in vitro and in vivo. Clinically, STX6 expression was significantly elevated in HCC tissues compared to it in para-tumor tissues. High STX6 expression predicted poor outcomes for patients following resection. Moreover, high expression of STX6 displayed low preventive efficacy of lenvatinib as a postoperative adjuvant treatment for HCC patients with a high risk of recurrence. Collectively, we identified that STX6-mediated autophagy plays a crucial role in lenvatinib resistance in HCC, providing a potential therapeutic target to overcome lenvatinib resistance for HCC patients.
Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: STX6 confers lenvatinib resistance of HCC.
Fig. 2: Lenvatinib induces autophagy in HCC cells.
Fig. 3: Lenvatinib-induced autophagy is mediated by STX6.
Fig. 4: Interaction of STX6 with Beclin1, VTI1A, and VAMP3 facilitates autophagy to confer lenvatinib resistance.
Fig. 5: STX6 promotes HCC progression.
Fig. 6: High expression of STX6 predicts poor prognosis of patients with HCC and resistance to lenvatinib adjuvant treatment.
Data availability
The RNA sequencing data of lenvatinib-resistant and their corresponding parental HCC cells have been publicly deposited at Gene Expression Omnibus (GEO accession number: GSE285575). All data are contained within the article. Requests for reagents should be addressed to Shao-Qiang Li (lishaoq@mail.sysu.edu.cn).
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
PubMedGoogle Scholar
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–604.
PubMedPubMed CentralGoogle Scholar
Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, et al. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2023;20:203–22.
PubMedGoogle Scholar
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.
CASPubMedGoogle Scholar
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6:649–58.
PubMedGoogle Scholar
Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965–72.
CASPubMedGoogle Scholar
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: a subanalysis of the REFLECT study. J Hepatol. 2023;78:133–41.
CASPubMedGoogle Scholar
Abdrakhmanov A, Gogvadze V, Zhivotovsky B. To eat or to die: deciphering selective forms of autophagy. Trends Biochem Sci. 2020;45:347–64.
CASPubMedGoogle Scholar
Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013;19:428–46.
CASPubMedGoogle Scholar
Qureshi-Baig K, Kuhn D, Viry E, Pozdeev VI, Schmitz M, Rodriguez F, et al. Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway. Autophagy. 2020;16:1436–52.
CASPubMedGoogle Scholar
Lv Y, Zhang W, Zhao J, Sun B, Qi Y, Ji H, et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal Transduct Target Ther. 2021;6:108.
CASPubMedPubMed CentralGoogle Scholar
Bernardini JP, Brouwer JM, Tan IK, Sandow JJ, Huang S, Stafford CA, et al. Parkin inhibits BAK and BAX apoptotic function by distinct mechanisms during mitophagy. Embo J. 2019;38:e99916.
Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang JY, Ye F, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015;11:225–38.
PubMedPubMed CentralGoogle Scholar
Tong M, Che N, Zhou L, Luk ST, Kau PW, Chai S, et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J Hepatol. 2018;69:826–39.
CASPubMedGoogle Scholar
Xue ST, Li K, Gao Y, Zhao LY, Gao Y, Yi H, et al. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target. Autophagy. 2020;16:1823–37.
CASPubMedPubMed CentralGoogle Scholar
Pan J, Zhang M, Dong L, Ji S, Zhang J, Zhang S, et al. Genome-scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy. 2023;19:1184–98.
CASPubMedGoogle Scholar
Wu FQ, Fang T, Yu LX, Lv GS, Lv HW, Liang D, et al. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α. J Hepatol. 2016;65:314–24.
CASPubMedGoogle Scholar
Reverter M, Rentero C, Garcia-Melero A, Hoque M, Vilà de Muga S, Alvarez-Guaita A, et al. Cholesterol regulates Syntaxin 6 trafficking at trans-Golgi network endosomal boundaries. Cell Rep. 2014;7:883–97.
CASPubMedGoogle Scholar
Koike S, Jahn R. SNAREs define targeting specificity of trafficking vesicles by combinatorial interaction with tethering factors. Nat Commun. 2019;10:1608.
PubMedPubMed CentralGoogle Scholar
Nozawa T, Minowa-Nozawa A, Aikawa C, Nakagawa I. The STX6-VTI1B-VAMP3 complex facilitates xenophagy by regulating the fusion between recycling endosomes and autophagosomes. Autophagy. 2017;13:57–69.
CASPubMedGoogle Scholar
Deng G, Li C, Chen L, Xing C, Fu C, Qian C, et al. BECN2 (beclin 2) negatively regulates inflammasome sensors through ATG9A-Dependent but ATG16L1- and LC3-independent non-canonical autophagy. Autophagy. 2022;18:340–56.
CASPubMedGoogle Scholar
Li W, Li K, Wei H, Sun Y, Liao Y, Zou Y, et al. Syntaxin-6, a reliable biomarker for predicting the prognosis of patients with cancer and the effectiveness of immunotherapy. Cancers. 2022;15:27.
Zhou L, Wang Z, Chen X, Li X, Ge C, Min X, et al. Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis. Int J Biol Sci. 2023;19:3892–907.
CASPubMedPubMed CentralGoogle Scholar
Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, et al. ATP11B mediates platinum resistance in ovarian cancer. J Clin Investig. 2013;123:2119–30.
CASPubMedPubMed CentralGoogle Scholar
Xu XF, Xing H, Han J, Li ZL, Lau WY, Zhou YH, et al. Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China. JAMA Surg. 2019;154:209–17.
PubMedGoogle Scholar
Anlaş AA, Nelson CM. Soft microenvironments induce chemoresistance by increasing autophagy downstream of integrin-linked kinase. Cancer Res. 2020;80:4103–13.
PubMedPubMed CentralGoogle Scholar
Zhang S, Liu X, Abdulmomen Ali Mohammed S, Li H, Cai W, Guan W, et al. Adaptor SH3BGRL drives autophagy-mediated chemoresistance through promoting PIK3C3 translation and ATG12 stability in breast cancers. Autophagy. 2022;18:1822–40.
CASPubMedGoogle Scholar
Meng J, Liu K, Shao Y, Feng X, Ji Z, Chang B, et al. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy. Cell Death Dis. 2020;11:137.
CASPubMedPubMed CentralGoogle Scholar
Yang F, Hilakivi-Clarke L, Shaha A, Wang Y, Wang X, Deng Y, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78:1602–24.
PubMedGoogle Scholar
Kimura T, Jia J, Kumar S, Choi SW, Gu Y, Mudd M, et al. Dedicated SNAREs and specialized TRIM cargo receptors mediate secretory autophagy. Embo J. 2017;36:42–60.
CASPubMedGoogle Scholar
Song Z, Zhang G, Yu Y, Li S. A prognostic autophagy-related gene pair signature and small-molecule drugs for hepatocellular carcinoma. Front Genet. 2021;12:689801.
CASPubMedPubMed CentralGoogle Scholar
Zhang Q, Xiong L, Wei T, Liu Q, Yan L, Chen J, et al. Hypoxia-responsive PPARGC1A/BAMBI/ACSL5 axis promotes progression and resistance to lenvatinib in hepatocellular carcinoma. Oncogene. 2023;42:1509–23.
CASPubMedGoogle Scholar
Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer Res. 2023;83:89–102.
CASPubMedGoogle Scholar
Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730–4.
CASPubMedGoogle Scholar
Hu F, Song D, Yan Y, Huang C, Shen C, Lan J, et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. Nat Commun. 2021;12:3651.
CASPubMedPubMed CentralGoogle Scholar
Chow PM, Liu SH, Chang YW, Kuo KL, Lin WC, Huang KH. The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma. Cancer Lett. 2020;471:27–37.
CASPubMedGoogle Scholar
Wirth M, Joachim J, Tooze SA. Autophagosome formation-the role of ULK1 and Beclin1-PI3KC3 complexes in setting the stage. Semin Cancer Biol. 2013;23:301–9.
CASPubMedGoogle Scholar
Galluzzi L, Green DR. Autophagy-independent functions of the autophagy machinery. Cell. 2019;177:1682–99.
CASPubMedPubMed CentralGoogle Scholar
Corona AK, Jackson WT. Finding the middle ground for autophagic fusion requirements. Trends Cell Biol. 2018;28:869–81.
CASPubMedPubMed CentralGoogle Scholar
Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, et al. RNA m(6) A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. Embo j. 2020;39:e103181.
CASPubMedPubMed CentralGoogle Scholar
Liu X, Zhang R, Liu L, Zhi S, Feng X, Shen Y, et al. Sohlh2 promotes the progression of hepatocellular carcinoma via TGM2-Mediated Autophagy. Mol Carcinog. 2024;64:138–51.
Huang X, Gan G, Wang X, Xu T, Xie W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15:1258–79.
CASPubMedPubMed CentralGoogle Scholar
Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17:528–42.
CASPubMedGoogle Scholar
Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective. Cell. 2019;176:11–42.
CASPubMedPubMed CentralGoogle Scholar
Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19:12.
CASPubMedPubMed CentralGoogle Scholar
Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021;14:16.
CASPubMedPubMed CentralGoogle Scholar
Kim HI, An J, Kim JY, Shin HP, Park SY, Song GW, et al. Postresection period-specific hazard of recurrence as a framework for surveillance strategy in patients with hepatocellular carcinoma: a multicenter outcome study. Liver Cancer. 2022;11:141–51.
PubMedGoogle Scholar
Download references
Funding
This work was supported by the National Natural Science Foundation of China (No.82072663) and the China Postdoctoral Science Foundation (No.2024M763772).
Author information
Author notes
These authors contributed equally: Guo-Pei Zhang, Ze-Bing Song, De-Hua Chen.
Authors and Affiliations
Department of Liver Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Guo-Pei Zhang, Ze-Bing Song, De-Hua Chen, Yang Yu, Fei-Feng Wu, Ming Kuang & Shao-Qiang Li
Authors
Guo-Pei Zhang
View author publications
You can also search for this author inPubMedGoogle Scholar
2. Ze-Bing Song
View author publications
You can also search for this author inPubMedGoogle Scholar
3. De-Hua Chen
View author publications
You can also search for this author inPubMedGoogle Scholar
4. Yang Yu
View author publications
You can also search for this author inPubMedGoogle Scholar
5. Fei-Feng Wu
View author publications
You can also search for this author inPubMedGoogle Scholar
6. Ming Kuang
View author publications
You can also search for this author inPubMedGoogle Scholar
7. Shao-Qiang Li
View author publications
You can also search for this author inPubMedGoogle Scholar
Contributions
SQL and GPZ conceived of the study. ZBS, GPZ, and DHC were involved in data acquisition and interpretation. YY and FFW contributed to the statistical analysis. GPZ and ZBS wrote the original manuscript. MK reviewed the manuscript and patient management. SQL supervised the study and reviewed the manuscript. All authors read and approved the manuscript.
Corresponding author
Correspondence to Shao-Qiang Li.
Ethics declarations
Competing interests
The authors declared no competing interests.
Ethical approval
All animal experiments were approved by the Institutional Care and Animal Use Committee of the First Affiliated Hospital of Sun Yat-sen University (Approval No [2021]308). We have obtained patients’ consent for publication. All human specimens were approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University (Approval No [2021]388). All methods were performed in accordance with the relevant guidelines and regulations.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary Material
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Zhang, GP., Song, ZB., Chen, DH. et al. Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma. Oncogene (2025). https://doi.org/10.1038/s41388-025-03371-7
Download citation
Received:29 September 2024
Revised:06 March 2025
Accepted:24 March 2025
Published:03 April 2025
DOI:https://doi.org/10.1038/s41388-025-03371-7
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative